KDM1A and acute myeloid leukemia: TCP and other more selective and potent LSD1-inhibitors like ORY-1001, ORY-2001, or IMG-7289 are currently investigated in a number of early phase clinical trials in different conditions, including AML, MPN, MDS, solid cancers, Alzheimer’s, and multiple sclerosis [83,186] (Figure 3).